Patents by Inventor Ndieme THIAM

Ndieme THIAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY ANTI IL17
    Publication number: 20230375545
    Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoanitibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
    Type: Application
    Filed: May 19, 2023
    Publication date: November 23, 2023
    Inventors: Pierre MIOSSEC, Ndieme THIAM, Jean-Jacques PIN
  • Anti-IL17A autoantibodies for treating or reducing the likelihood of occurrence of bone destruction associated with a chronic autoimmune or inflammatory disease
    Patent number: 11693003
    Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 4, 2023
    Assignees: Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio Scientific
    Inventors: Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
  • Biological marker for evaluating the IL-17 pro-inflammatory functional contribution dependent level in an individual
    Patent number: 11079391
    Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 3, 2021
    Assignees: Hospices Civils de Lyon, Universite Claude Bernard Lyon 1
    Inventors: Pierre Miossec, Ndieme Thiam
  • ANTIBODY ANTI IL17
    Publication number: 20190137489
    Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.
    Type: Application
    Filed: April 24, 2017
    Publication date: May 9, 2019
    Inventors: Pierre MIOSSEC, Ndieme THIAM, Jean-Jacques PIN
  • BIOLOGICAL MARKER FOR EVALUATING THE IL-17 PRO-INFLAMMATORY FUNCTIONAL CONTRIBUTION DEPENDENT LEVEL IN AN INDIVIDUAL
    Publication number: 20170176456
    Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).
    Type: Application
    Filed: June 5, 2015
    Publication date: June 22, 2017
    Inventors: Pierre MIOSSEC, Ndieme THIAM